Objectives: To review the published literature of the past 15 years regarding use of calcium channel blockers (CCBs) in psychiatric practice. These drugs, especially verapamil, have been recommended as possible treatments for mania and other disorders.
Studies of shifts in serum calcium concentrations led to the hypothesis that these may determine the switch process in manic-depressive disorder and other periodic psychoses. However, such measurements are rather insensitive because ofthe exquisite homeostatic regulation ofserum calcium levels (2) . Free intracellular calcium-ion concentrations are elevated in platelets and lymphocytes of manic and bipolar depressed patients but not in control or unipolar depressed patients or in patients made euthymic by various medications or electroconvulsive therapy (ECT). Increased activity ofleukocyte receptor-linked G-proteins and activation of the platelet phosphoinositol (PI) system have been observed in membrane preparations ofuntreated manic patients. Such findings suggest a defect present in mood disorders that allows calcium ions to enter into cells too easily. Drugs such as lithium and carbamazepine, both effective for treating mania, also tend to reverse these changes. Some antipsychotics of the The most compelling argument for the use ofcalcium channel blockers (CCBs) is that the influx of calcium from the extracellular fluid to the cytosol ofcells through calcium channels is important for the release of neurotransmitters from presynaptic neurons (4) . Thus CCBs might act presynaptically rather than block receptors postsynaptically. Although the earliest material with calcium-channel blocking effects, magnesium ion, was reported long ago to ameliorate excited psychotic states (5), only during the past 2 decades have clinical studies attempted to elucidate the actions ofthe present group of CCBs. Three distinct chemical classes of these drugs are being studied; not only do they differ chemically, but they differ in the molecular mechanisms oftheir pharmacological actions; thus, they are not interchangeable, and it is possible that one or another class may show some selectivity of action. Further, present CCBs were screened primarily on the basis of their cardiovascular action; other compounds might be found which are more selective for action on the central nervous system (CNS). Among existing drugs, only nimodipine is thought to have greater access to the nervous system because of increased lipid solubility.
This review assesses the literature of the past 2 decades concerning the use of CCBs in psychiatry. Reports have been grouped according to the degree of control used, from those with no attempts at control (usually published as letters or brief communications) to those that have used many of the techniques of acceptable controlled trials. Also, studies have been somewhat categorized by diagnosis: bipolar disorder, depression, schizophrenia, and various other disorders, ranging from panic reactions to Huntington's disease. Depressed patients figured in 6 reports and involved 23 patients. Improvement was reported in 15 patients, while 2 became depressed when treated with nifedipine for cardiovascular indications. The assumption is that these cases represented unipolar depression rather than bipolar depression. In addition to the 2 patients whose depression had been precipitated by nifedipine, 1 patient with mania also experienced depression during treatment with this drug for hypertension. These reports suggested that possibly nifedipine has depressogenic actions. Only 6 of 59 patients with schizophrenia responded. It must be emphasized that most of these patients were chronically ill and unresponsive to most other treatments. In one of these reports, it was felt that symptoms and signs oftardive dyskinesia improved. An additional case report indicated another patient with tardive dyskinesia who responded. A brief report of verapamil in 9 patients withtardive dyskinesia revealed a small mean decrease in abnormal movement scale scores, but the clinical benefit in individual patients was impossible to assess.
Results

Uncontrolled Reports
Partially Controlled Studies
In these studies, some control was used, most often the substitution of placebo for the active drug. There was no evidence that any of these studies were blinded. Results are summarized in Table 2 . Verapamil improved manic symptoms in 2 patients treated in separate studies. Another patient with mania phenelzine also improved. Two other patients with rapidcycling mania improved but the reason was not clear. Of 12 patients with "affective dysregulation" treated in a singleseries, 5 were improved, 4 were unimproved, and 3 were not evaluable. In summary, verapamil improved 8 patients, failed to improve 4, and results were not evaluable for 5. One patient with depression showed a decrease in Hamilton Depression Rating Scale score during treatment with verapamil. Twelve schizophrenia patients treated with verapamil showed no response.
Aswas the case with the uncontrolled studies, those with partialcontrols also suggested that CCBs were effective in mania but were ineffective for schizophrenia. The issue with depressed patients was not clear.
Controlled Studies
These studies compared verapamil with placebo (3 studies), lithium(3 studies), or clonidine (1 study) in 115 patients with mania (Table 3) . It is not clear that all of these studies were blind. When compared with placebo, in 2 small studies verapamilproved better in 12 of 15 patients. In a larger controlled trial, 5 of 15 patients treated with placebo and 7 of 17 patients treated with verapamil showed an improvement of 20% to 40% above baseline, a difference that was not significant (55) . The maximum dose of verapamil was 240 mg daily, which might have been small. It was also better than clonidine, a drug for which scant evidence of efficacy exists. In comparisonwith lithium, it was better in one study, no different in another, and less effective in the third.
The first controlled trial to use the classical randomassignment parallel-group double-blind design found no difference between the 2 treatments (57). However, the number ofpatients who completed the study was in the single digits in both groups, raising a strong possibility ofinadequate statistical power to reject the null hypothesis. In both treatment groups the improvement noted was rather small. The best study to date used 40 patients to compare verapamil with lithium, also using a classical controlled design. In this study, lithium was defmitely superior to verapamil on several rating scales (58) .
This study, along with one previously cited in which no difference was found between verapamil and placebo, would seem to take verapamil out of contention as first-line treatment for mania. Four controlled trials compared CCBs with placebo (3 cases) or haloperidol (1 case) in patients with schizophrenia. Two trials, including one with 8 patients treated with verapamil and 5 patients treated with nifedipine found no more effect than with placebo (60, 63) . Conversely, a trial comparing another dihydropyridine CCB, nivaldipine, found a minimal decrease in Brief Psychiatric Rating Scale (BPRS) scores after nivaldipine; it is unlikely that any clinically discernible benefits could have been noted. No effect on tardive dyskinesia was noted (62) . Thus, controlled trials, just as the others, have had difficulty in showing a therapeutic effect of CCBs in schizophrenia.
Perhaps the best controlled trial ofCCBs involved 86 patients with depression who were randomly assigned to treatment with verapamil, amitriptyline, placebo, or elective treatment. Amitriptyline and elective treatment were superior to either verapamil or placebo. This fairly large-scale study, with a reasonably adequate design, should lay to rest any ambiguity about the role of CCBs in the treatment of depression (59) .
A role for these drugs in the treatment ofAlzheimer-type dementia has been recently explored. Among 178 patients with "cognitive decline," veraparnil was superior to placebo in patients both with Alzheimer's disease and with vascular dementia (64) . In another series of 227 patients, those treated with nimodipine showed less progression of the illness over 12 months than those treated with placebo. These studies are somewhat encouraging, considering the dire implications of these disorders.
Several other small studies have attempted to assess CCBs as treatments for tardive dyskinesia (some support), Huntington's disease (no effect), and panic disorder (equivocal).
Discussion
We have attempted to review completely the literature on CCBs in the treatment ofpsychiatric disorders. We doubt that the review is complete, but it is as much so as the availability of various journals affords. The evidence in this case is such that any kind of metaanalysis would be totally impossible. We have given weight to what we consider to be the best studies to date. Here are some possible conclusions:
Considering that CCBs have been investigated for the past 15 years, the number of reports has been rather small, and the number published yearly does not seem to be increasing, as it might with an effective therapy. Several possible reasons can be considered to account for this unimpressive level of interest. One might be that reporting has been subject to selection bias, with only those reports claiming benefit reaching the literature, while unreported clinical experience has been largely negative or at least unimpressive. Another reason is that drug companies selling the various drugs under discussion have not pursued studies of efficacy with the goal of obtaining a New Drug Application for a new indication. One of us proposed such a study in 1984 to the director of clinical investigation of the company then selling verapamil. The proposal was met with polite inattention. Is such reticence based on private information counselling conservatism, or the possibility that patent protection might be lost before the new indications could be established, or simple marketing considerations? In any case, without a sponsoring drug company actively pursuing a new indication, reports on the drug may be expected to be relatively few. The diffidence ofdrug com. panies has been commented on elsewhere, with the suggestion that a j oint private-governmental approach be attempted to settle the issue (69) .
Mania has been the major indication studied and the one that has the most possibility for benefit. Verapamil has been the CCB most studied, although one might make a case for more studies of nimodipine. Although results in mania have been mixed, the 2 best controlled studies of this disorder have shown no difference from placebo and less efficacy than lithium (55, 58) . It may be that, as some reports have indicated, verapamil might be considered only as an adjunct, to be used when lithium, valproate, or carbamazepine fails. A doubleblind study of the addition of verapamil to the treatment of such refractory patients might be helpful in settling what role, if any, verapamil has.
The best controlled study ofCCBs has been in depressed patients and the results are clearly negative. Unless future evidence support the contrary, this indication would not merit further testing. Fragmentary evidence suggests that one drug, nifedipine, may actually be depressogenic. Controlled trials in patients with schizophrenia have been mostly negative. However, including neuroleptic-refractory patients in many ofthese trials might provide for negative bias. Even so, theincreasing number of neuroleptics would mitigate any further interest in a drug with so little credibility. Ofthe remainingindications that have been tested, tardive dyskinesia is of greatest possible interest. One placebo-controlled trial suggested some utility (63) . As few other treatments are effective, more experience with this indication is needed.
Remarkably, the prevalence ofside effects and complications of treatment with verapamil in psychiatric patients has been small, certainly no greater than those encountered whenthese drugs are used for other approved indications, such as angina pectoris or hypertension. Nor has there been any indication of unexpected drug interactions with other antimanic drugs or neuroleptics used concurrently. Recently, a pall has been cast on one member of this class, nifedipine, the short-actingversion ofwhich has been associated with an increased incidence of cardiac events and cancer (70, 71) . Even if these reports were confirmed, which they have not been, the poor therapeutic compared with possible side effects would militate against the use of nifedipine in psychiatric disorders.
Thus at this moment, not enough evidence is available to accept verapamil as an effective therapeutic agent for psychiatric disorders, other than possibly for mania. Nor is there any reason to believe that this situation might soon change. No new drug applications are on file for pursuing these indications. Yet, enough interest in these drugs has been promoted so as to devote a chapter in a recent psychopharmacology text to these drugs (72) .
A recent review of CCBs in various neuropsychiatric disorders made little mention of their use in psychiatric disorders other than dementia. The review did point out that current CCBshave been arbitrarily selected for actions on the cardiovascular system. Should drugs more appropriate to the CNS ultimately be developed, renewed investigations might be in order (73) .
